Some people with advanced colorectal cancer are resistant to some types of chemotherapy, and a mutation in the so-called TFAP2E gene may play a part in that resistance, German researchers report. Knowing which patients carry the mutation might help doctors tailor treatments or develop new targets for therapy, the researchers said.
